Cargando…

Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-trans Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle Formulation

Type 1 diabetes (T1D) is a disorder of impaired glucoregulation due to lymphocyte-driven pancreatic autoimmunity. Mobilizing dendritic cells (DC) in vivo to acquire tolerogenic activity is an attractive therapeutic approach as it results in multiple and overlapping immunosuppressive mechanisms. Deli...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Brett E., Garciafigueroa, Yesica, Engman, Carl, Liu, Wen, Wang, Yiwei, Lakomy, Robert J., Meng, Wilson S., Trucco, Massimo, Giannoukakis, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982719/
https://www.ncbi.nlm.nih.gov/pubmed/33763059
http://dx.doi.org/10.3389/fimmu.2021.586220
_version_ 1783667777790279680
author Phillips, Brett E.
Garciafigueroa, Yesica
Engman, Carl
Liu, Wen
Wang, Yiwei
Lakomy, Robert J.
Meng, Wilson S.
Trucco, Massimo
Giannoukakis, Nick
author_facet Phillips, Brett E.
Garciafigueroa, Yesica
Engman, Carl
Liu, Wen
Wang, Yiwei
Lakomy, Robert J.
Meng, Wilson S.
Trucco, Massimo
Giannoukakis, Nick
author_sort Phillips, Brett E.
collection PubMed
description Type 1 diabetes (T1D) is a disorder of impaired glucoregulation due to lymphocyte-driven pancreatic autoimmunity. Mobilizing dendritic cells (DC) in vivo to acquire tolerogenic activity is an attractive therapeutic approach as it results in multiple and overlapping immunosuppressive mechanisms. Delivery of agents that can achieve this, in the form of micro/nanoparticles, has successfully prevented a number of autoimmune conditions in vivo. Most of these formulations, however, do not establish multiple layers of immunoregulation. all-trans retinoic acid (RA) together with transforming growth factor beta 1 (TGFβ1), in contrast, has been shown to promote such mechanisms. When delivered in separate nanoparticle vehicles, they successfully prevent the progression of early-onset T1D autoimmunity in vivo. Herein, we show that the approach can be simplified into a single microparticle formulation of RA + TGFβ1 with surface decoration with the T1D-relevant insulin autoantigen. We show that the onset of hyperglycemia is prevented when administered into non-obese diabetic mice that are at the mid-stage of active islet-selective autoimmunity. Unexpectedly, the preventive effects do not seem to be mediated by increased numbers of regulatory T-lymphocytes inside the pancreatic lymph nodes, at least following acute administration of microparticles. Instead, we observed a mild increase in the frequency of regulatory B-lymphocytes inside the mesenteric lymph nodes. These data suggest additional and potentially-novel mechanisms that RA and TGFβ1 could be modulating to prevent progression of mid-stage autoimmunity to overt T1D. Our data further strengthen the rationale to develop RA+TGFβ1-based micro/nanoparticle “vaccines” as possible treatments of pre-symptomatic and new-onset T1D autoimmunity.
format Online
Article
Text
id pubmed-7982719
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79827192021-03-23 Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-trans Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle Formulation Phillips, Brett E. Garciafigueroa, Yesica Engman, Carl Liu, Wen Wang, Yiwei Lakomy, Robert J. Meng, Wilson S. Trucco, Massimo Giannoukakis, Nick Front Immunol Immunology Type 1 diabetes (T1D) is a disorder of impaired glucoregulation due to lymphocyte-driven pancreatic autoimmunity. Mobilizing dendritic cells (DC) in vivo to acquire tolerogenic activity is an attractive therapeutic approach as it results in multiple and overlapping immunosuppressive mechanisms. Delivery of agents that can achieve this, in the form of micro/nanoparticles, has successfully prevented a number of autoimmune conditions in vivo. Most of these formulations, however, do not establish multiple layers of immunoregulation. all-trans retinoic acid (RA) together with transforming growth factor beta 1 (TGFβ1), in contrast, has been shown to promote such mechanisms. When delivered in separate nanoparticle vehicles, they successfully prevent the progression of early-onset T1D autoimmunity in vivo. Herein, we show that the approach can be simplified into a single microparticle formulation of RA + TGFβ1 with surface decoration with the T1D-relevant insulin autoantigen. We show that the onset of hyperglycemia is prevented when administered into non-obese diabetic mice that are at the mid-stage of active islet-selective autoimmunity. Unexpectedly, the preventive effects do not seem to be mediated by increased numbers of regulatory T-lymphocytes inside the pancreatic lymph nodes, at least following acute administration of microparticles. Instead, we observed a mild increase in the frequency of regulatory B-lymphocytes inside the mesenteric lymph nodes. These data suggest additional and potentially-novel mechanisms that RA and TGFβ1 could be modulating to prevent progression of mid-stage autoimmunity to overt T1D. Our data further strengthen the rationale to develop RA+TGFβ1-based micro/nanoparticle “vaccines” as possible treatments of pre-symptomatic and new-onset T1D autoimmunity. Frontiers Media S.A. 2021-03-08 /pmc/articles/PMC7982719/ /pubmed/33763059 http://dx.doi.org/10.3389/fimmu.2021.586220 Text en Copyright © 2021 Phillips, Garciafigueroa, Engman, Liu, Wang, Lakomy, Meng, Trucco and Giannoukakis. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Phillips, Brett E.
Garciafigueroa, Yesica
Engman, Carl
Liu, Wen
Wang, Yiwei
Lakomy, Robert J.
Meng, Wilson S.
Trucco, Massimo
Giannoukakis, Nick
Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-trans Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle Formulation
title Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-trans Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle Formulation
title_full Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-trans Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle Formulation
title_fullStr Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-trans Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle Formulation
title_full_unstemmed Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-trans Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle Formulation
title_short Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-trans Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle Formulation
title_sort arrest in the progression of type 1 diabetes at the mid-stage of insulitic autoimmunity using an autoantigen-decorated all-trans retinoic acid and transforming growth factor beta-1 single microparticle formulation
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982719/
https://www.ncbi.nlm.nih.gov/pubmed/33763059
http://dx.doi.org/10.3389/fimmu.2021.586220
work_keys_str_mv AT phillipsbrette arrestintheprogressionoftype1diabetesatthemidstageofinsuliticautoimmunityusinganautoantigendecoratedalltransretinoicacidandtransforminggrowthfactorbeta1singlemicroparticleformulation
AT garciafigueroayesica arrestintheprogressionoftype1diabetesatthemidstageofinsuliticautoimmunityusinganautoantigendecoratedalltransretinoicacidandtransforminggrowthfactorbeta1singlemicroparticleformulation
AT engmancarl arrestintheprogressionoftype1diabetesatthemidstageofinsuliticautoimmunityusinganautoantigendecoratedalltransretinoicacidandtransforminggrowthfactorbeta1singlemicroparticleformulation
AT liuwen arrestintheprogressionoftype1diabetesatthemidstageofinsuliticautoimmunityusinganautoantigendecoratedalltransretinoicacidandtransforminggrowthfactorbeta1singlemicroparticleformulation
AT wangyiwei arrestintheprogressionoftype1diabetesatthemidstageofinsuliticautoimmunityusinganautoantigendecoratedalltransretinoicacidandtransforminggrowthfactorbeta1singlemicroparticleformulation
AT lakomyrobertj arrestintheprogressionoftype1diabetesatthemidstageofinsuliticautoimmunityusinganautoantigendecoratedalltransretinoicacidandtransforminggrowthfactorbeta1singlemicroparticleformulation
AT mengwilsons arrestintheprogressionoftype1diabetesatthemidstageofinsuliticautoimmunityusinganautoantigendecoratedalltransretinoicacidandtransforminggrowthfactorbeta1singlemicroparticleformulation
AT truccomassimo arrestintheprogressionoftype1diabetesatthemidstageofinsuliticautoimmunityusinganautoantigendecoratedalltransretinoicacidandtransforminggrowthfactorbeta1singlemicroparticleformulation
AT giannoukakisnick arrestintheprogressionoftype1diabetesatthemidstageofinsuliticautoimmunityusinganautoantigendecoratedalltransretinoicacidandtransforminggrowthfactorbeta1singlemicroparticleformulation